Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug…
Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has…
Hypertension affects nearly half of all adults in the United States – 47% or 116 million people, some of which are medication-resistant A recent study from the University of Toledo College of Medicine and Life…
Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertension A 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last…
Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from…
Lexaria is the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology DehydraTECH is designed to enhance the performance of fat-soluble active pharmaceutical ingredients (“APIs”), molecules, and drugs by increasing their bioavailability Through animal…
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently received its 27th worldwide patent, granted in Mexico under registration #390001. “The patent applies to a range of active ingredients, including but…
Lexaria is a global innovator in drug delivery platforms whose lead technology is DehydraTECH(TM) Studies have shown that DehydraTECH increases the intestinal bioabsorption of bioactive compounds by as much as 27 times, hence resulting in…
Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been…
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is focused on establishing a stronghold in the $28 billion hypertension drug market. The company’s exclusive therapeutic, DehydraTECH-CBD, has shown exciting potential as an alternative…
Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the world Its…
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a…
Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIs The company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its…
Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EU The patent allows the company to provide value in gaining…
Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technology The company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to…
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board.…
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is continuing to accumulate international patents; most recently the company received its 27th patent granted worldwide. Part of Lexaria’s third patent family — Stable Ready-to-Drink Beverage…
Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point Since the company began developing its…
Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued Based…
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier…